Clinical Trial

Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 14, 2023 (before its estimated December 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent analysis system based on radiomics. By extracting and combining the radiomics features related to peritoneal metastasis of gastric cancer, the intelligent analysis system could predict the risk of peritoneal metastasis, and provide personalized decision suggestions for the treatment of gastric cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-02-01.
Trial Details
NCT Number NCT05722275
Lead Sponsor Chinese Academy of Sciences
Collaborators: Peking University Cancer Hospital & Institute, Zhenjiang First People's Hospital, The First Affiliated Hospital of Zhengzhou University, Nanfang Hospital, Southern Medical University, Guizhou Provincial People's Hospital, Henan Cancer Hospital, Yunnan Cancer Hospital, Guangdong Provincial People's Hospital, Guangzhou Medical University, Fujian Medical University Union Hospital, Shanxi Province Cancer Hospital, Sun Yat-sen University, Beihang University, Scientific Institute San Raffaele
Conditions Gastric Cancer, Peritoneal Metastases
Enrollment 400 participants
Start Date 2023-01-01
Primary Completion 2023-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-02-14